Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: iStock
Uganda has officially ended the Ebola outbreak after completing the mandatory 42-day monitoring period with no new infections, even as neighboring Democratic Republic of the Congo (DRC) continues to battle its worst outbreak of the deadly disease in years.
Ugandan Health Minister Chris Baryomunsi announced the "successful completion of the mandatory 42-day monitoring period," which began after the last locally transmitted patient was discharged on June 16.
"Throughout this period, the Ministry of Health maintained intensive surveillance nationwide, and no new Ebola cases have been detected," Baryomunsi said.
Earlier this month, Dr. Diana Atwine, Permanent Secretary at Uganda's Ministry of Health, said the outbreak had been successfully contained through rapid surveillance, prompt treatment, contact tracing, and close cross-border coordination.
Uganda recorded 20 confirmed Ebola cases during the outbreak. Of these, 18 patients recovered and were discharged, while two died.
Most of the infections were linked to travelers arriving from the DRC, with only a small number resulting from local transmission.
Despite the declaration, Baryomunsi urged the public to remain "vigilant" and continue following public health measures to prevent future outbreaks.
Also read: Michigan Cyclosporiasis Outbreak Nears 10,000 Cases: Is Your Lettuce Safe?
While Uganda celebrates its success, the Ebola crisis in the DRC continues to worsen. According to the Congolese Ministry of Health, the country has reported at least 3,262 cases and 1,437 deaths, bringing the outbreak close to the scale of the country's devastating 2018-2020 epidemic.
The World Health Organization (WHO) has described it as the fastest-spreading Ebola outbreak ever recorded, warning that the actual number of infections could be two to four times higher than officially reported.
United Nations humanitarian officials have described the outbreak as one of the world's most severe public health emergencies.
"The outbreak is spreading like wildfire," UN officials warned, citing armed conflict, mass displacement, and repeated attacks on healthcare facilities as major obstacles to controlling the virus.
The WHO has also warned that many newly reported infections cannot be linked to known transmission chains, suggesting the virus is spreading undetected within communities.
Contact tracing remains inadequate, while insecurity, misinformation, and community mistrust continue to undermine response efforts.
Health workers have also staged strikes in some areas over unpaid wages, further disrupting patient care and containment operations.
Attacks on health facilities, shortages of medical supplies, delayed laboratory testing, and public distrust are other factors delaying efforts to isolate patients, trace contacts, and break chains of transmission.
Amid the worsening outbreak, researchers have reached an important milestone in Ebola vaccine development.
The first volunteer has received an experimental vaccine targeting the Bundibugyo strain of Ebola, marking the world's first Phase I clinical trial for this virus, according to the University of Oxford.
The vaccine, ChAdOx1 BDBV, developed in collaboration with Serum Institute of India (SII), is designed specifically to protect against the Bundibugyo strain of Ebola.
It uses the same viral vector platform that powered the Oxford-AstraZeneca COVID-19 vaccine.
The vaccine uses a genetically modified chimpanzee adenovirus (ChAdOx1)—a harmless virus that normally causes the common cold in chimpanzees—as a delivery vehicle.
"We welcome the start of the phase 1 clinical trial of an investigational vaccine against Ebola Bundibugyo virus disease—an important step to assess the safety and immune responses generated by the vaccine," said WHO Director-General Tedros Adhanom Ghebreyesus on X.
Credit: AI
A simple blood test that can accurately identify tuberculosis (TB) across people with different levels of exposure help earlier diagnosis and speedy treatment,, according to new research presented at the Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Scientific Meeting.
The study discovered that the experimental blood test can distinguish individuals with active tuberculosis from those who are healthy, regardless of whether they have had prior exposure to the disease.
Researchers say the findings could help address one of the biggest hurdles in TB control: identifying and tracing infectious patients before they unknowingly spread the disease.
"If validated in larger clinical studies, this test has the potential to transform tuberculosis screening by enabling earlier and more accurate detection of active disease," the study authors said. They observed that such a tool can significantly help control transmission, particularly in nations where TB still remains a public health issue.
Although TB is preventable and curable, delayed diagnosis continues to fuel transmission and contributes to deaths that are preventable.
Current diagnostic methods have important limitations. Sputum-based tests can be difficult to perform, especially in children and people with TB outside the lungs.
Meanwhile, commonly used blood tests can indicate exposure to the bacteria but cannot reliably distinguish between active disease and latent infection, meaning additional investigations are needed.
Also read: World Tuberculosis Day: A 2nd Surge In Tuberculosis Cases Again Seen In The US
According to the researchers, the new test examines the immune signatures in a blood sample to identify active tuberculosis, rather than merely detecting previous exposure.
In the study, the test successfully differentiated active TB cases from healthy individuals with varying degrees of TB exposure, suggesting it could be used as an effective screening tool across diverse populations.
The investigators emphasized that larger, multi-center studies are still needed before the test can become part of routine clinical practice. However, the early results point toward a faster and less invasive way of diagnosis.
Also read: Over 8 Million People Diagnosed With TB Last Month: Know Early Signs
Early diagnosis is one of the most factors for controlling tuberculosis. Patients with untreated active TB can infect many others. A simple blood test that identifies active disease quickly could allow doctors to start treatment sooner, reduce transmission, and improve patient's health.
This could also be useful where resources are particularly limited. Places where collecting sputum samples is challenging and access to a sterile laboratory testing is limited can benefit from this blood test.
As blood samples are easier to obtain in many clinical situations, the test could help screen vulnerable populations, including children and people with extrapulmonary TB.
Public health experts have repeatedly stressed that improved diagnostics are essential for achieving the World Health Organization's End TB Strategy.
Treating latent TB is like stopping the virus, while it's still small and easy to treat. It's much easier to kill the dormant germs than to fighting the active disease. You could be carrying the disease and not realise. This increases the risk of transmission.
A 2017 study published in the Viruses Journal explained that we all have slightly different versions of our genes (polymorphisms) and these differences can affect how our bodies react to any virus. Some gene variations might make your immune system stronger against a specific virus, while others might make you more vulnerable.
Credit: iStock
Michigan, the hardest-hit state in the ongoing nationwide cyclosporiasis outbreak, has reported nearly 10,000 cases of the intestinal illness, which can cause severe, often "explosive," diarrhea, according to state health officials.
So far, the state has recorded 160 hospitalizations, with no deaths reported.
According to the US Centers for Disease Control and Prevention (CDC), 6,707 laboratory-confirmed domestic cases of cyclosporiasis have been reported since May 1.
The agency also said it is tracking more than 11,500 additional suspected cases that have not yet been laboratory confirmed or remain under investigation. Many of these reports have come from Michigan and Ohio.
A US Food and Drug Administration (FDA) investigation has linked part of the outbreak to iceberg lettuce served at Taco Bell restaurants and supplied through Taylor Farms operations in central Mexico.
The FDA is continuing to investigate other potential sources of contamination. Taco Bell has stopped serving the affected lettuce, while Taylor Farms has voluntarily recalled dozens of iceberg lettuce products distributed across 27 states. The company also said it will no longer source iceberg lettuce from central Mexico for the remainder of the growing season.
The recalled lettuce has been linked to illnesses in five states—Indiana, Kentucky, Michigan, Ohio, and West Virginia. However, investigators have not yet determined how many illnesses are directly connected to the recalled products.
Separately, the FDA is investigating another Cyclospora outbreak that is unrelated to the lettuce-linked cases. The second outbreak has sickened 72 people and has been traced to an unidentified food item. The agency said the source has "not yet been identified."
Former CDC Director Robert Redfield told media that the US government may consider ending produce sourcing from central Mexico. He also suggested the outbreak may involve more than lettuce.
Officials are also investigating whether parsley and cilantro, in addition to lettuce, could be associated with the outbreak. The investigation is ongoing.
The FDA advises consumers to check salad and lettuce products purchased during the past week to determine whether they were sourced from Taylor Farms de Mexico in Guanajuato, Mexico.
The recalled retail products include:
Consumers who purchased these products should throw them away or return them to the store where they were bought.
An additional 33 recalled lettuce products were distributed to restaurants and other food-service businesses and are unlikely to be found in home refrigerators. A complete list of recalled products is available on the FDA website.
At this time, no other lettuce varieties—including romaine or butter lettuce—have been linked to the outbreak, even if distributed by Taylor Farms. The company told Newsweek that, aside from the recalled iceberg lettuce, "no other Taylor Fresh Foods products across the country are impacted."
Health officials recommend:
© 2024 Bennett, Coleman & Company Limited